In this online, self-learning activity:
Interstitial lung disease (ILD) is a collective term used to categorize more than 200 different types of diseases that affect the alveolar structures, the pulmonary interstitium, and small airways. The incidence and prevalence of ILD, as its own entity, are difficult to quantify because of number of different causes and the difficulty diagnosing patients. One form of ILD is associated with an overexpression of adenosine-2B receptor (A2BAR) has been linked to rapid progression of idiopathic pulmonary fibrosis (IPF), a type of IIP, and patients identified with this highly upregulated gene warrants closer monitoring of lung function and disease progression. Known as ILD with progressive lung phenotype (ILD-PF), patients with a number of diseases, such as rheumatoid arthritis and chronic hypersensitivity pneumonitis, are predisposed to this variant. This learning activity has been designed to bring HCPs’ knowledge of the strategies for treatment and management of ILD-PF up to date and to improve their competence and performance in treating it.
The following HCPs: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with ILD-PF.
This program is supported by an educational grant from Boehringer Ingelheim.
Release Date: January 27, 2019 -- Expiration Date: January 27, 2021
Faculty: Terese Hammond, MD
Cursory refresher and review on ILD epidemiology and diagnosis and introduction to the PF variant
o Age, race, gender
o Environmental factors
o Genetics (A2BAR)
o Autoimmune diseases
o Immune dysfunction
o Overactivation of fibroblasts
o Dyspnea on exertion
o Nonproductive cough
o HRCT scan vs. chest radiography
o Lung biopsy
o Serological testing
Treatment of ILD-PF
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Dr. Terese C. Hammond, MD, Clinical Professor, University of Southern California, Los Angeles, CA has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.